Find Alternatives To Endologix AFX For Treating Abdominal Aortic Aneurysms, FDA Advises
Executive Summary
In its most recent update on the use of Endoglox AFX endovascular grafts, the US FDA is advising physicians use other devices for treating patients with abdominal aortic aneurysms (AAA). AFX still poses bleeding risk.
You may also be interested in...
FDA Stresses Need For Routine Monitoring Of Endovascular Aortic Repair Patients
A new letter to providers says that to ensure potential adverse events can be identified early, patients should be checked via imaging at 30 days after surgery and at least once a year thereafter.
Bleeding Risks Still A Concern For Patients With Endologix Stent Grafts: FDA Advisory Panel
The US agency’s Circulatory System Devices Panel found type III endoleaks are still a problem for abdominal aortic aneurysm patients treated with the newest Endologix stent graft, though for some the benefits still outweigh the risks. The panel advised that all patients, however, should continue getting annual screenings.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.